…And Slam Dunk Pulls Ahead of the Pack to Win by a Mile!!!

secretariat1It wasn’t even a photo finish!

Neuren’s trial was a double-blind, randomized, placebo controlled study that tested three doses of trofinetide compared with placebo in 82 subjects.  The highest dose of trofinetide achieved statistically significant clinical benefit compared with placebo for each of three syndrome-specific efficacy measures, the Rett Syndrome Behaviour Questionnaire (p=0.042), the Clinical Global Impression of Improvement (p=0.029) and the Rett Syndrome Domain Specific Concerns (p=0.025).  These measures included assessments of both clinicians and caregivers.  Clinical improvements of 15% to 16% from baseline were observed, which was considered by leading Rett syndrome physicians to be clinically meaningful, particularly in a short duration trial.  The improvement increased through to the time that treatment ceased.  This suggests that further benefit may be achieved with longer treatment duration.
These results provide strong evidence of biological activity of the high dose across multiple symptom areas, indicating the potential for disease modification rather than simply addressing isolated symptoms.  In addition, trofinetide was well tolerated and had a good safety profile in these younger subjects, with no dose-limiting effects observed.

And some commentators’ remarks on the brilliant finish…

 Dr Kaufmann commented:
“The outcome of this trial is very encouraging.  Safety, the primary goal, was achieved.  As important and with broad implications, there was a clear clinical improvement covering several common symptoms in Rett syndrome, which are known to impair the quality of life of girls affected by the disorder.  The variety of improved symptoms suggests that trofinetide is a drug that targets mechanisms underlying the disorder rather than a symptomatic medication.  Similar to the previous adult trial, the results are particularly significant because of the relatively short duration of the trial.  The impact of the study goes beyond the suggested efficacy of trofinetide, since it shows the potential of neurobiologically-based drugs for the treatment of Rett syndrome and other neurodevelopmental disorders.”
Alan Percy, MD, Professor of Neurology and Director of Clinical Neuroscience at the Civitan International Research Center & Sparks Clinics, The University of Alabama at Birmingham, was an investigator for this trial and for Neuren’s previous trial in adults and adolescents with Rett syndrome. :
“The clear results from this trial of trofinetide in children support and strengthen the promising results that were obtained in the Neuren trial in older individuals with Rett syndrome.  I now look forward to the pivotal trial.” 
Steve Kaminsky, PhD, Chief Science Officer of Rettsyndrome.org commented:
“These pediatric study results are very exciting.  The data suggest that trofinetide is having a positive change on a number of challenges of Rett syndrome.  We at Rettsyndrome.org are very proud to have supported this game-changing study, believing that the best is yet to come.”  
What a race! What a finish!!! Bring on Phase III.
And to Margaret Brimble and her team: we all owe you a debt so profound to our hearts as the earth owes the sun.
This entry was posted in Neuren Pharmaceuticals, Rett Research, Rett Syndrome, rettland.org, rettsyndrome.org, Trofinetide, Trofinetide Pediatric trial, Uncategorized and tagged , , . Bookmark the permalink.

2 Responses to …And Slam Dunk Pulls Ahead of the Pack to Win by a Mile!!!

  1. Rose and Renée says:

    Mel and Katie
    Thank you so much for keeping us all up to date with the trofinetide count downs, updates and most of all your participation in the trial.
    Always in my heart

  2. melelllan says:

    You are the sweetest, Rosemary. Give Renee a kiss from both if us. Xo

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s